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C O R O N A V I R U S
INSIGHT: A population-scale COVID-19 testing strategy 
combining point-of-care diagnosis with centralized 
high-throughput sequencing
Qianxin Wu1*, Chenqu Suo1,2*, Tom Brown3, Tengyao Wang4,  
Sarah A. Teichmann1,5†, Andrew R. Bassett1†
We present INSIGHT [isothermal NASBA (nucleic acid sequence–based amplification) sequencing–based high- 
throughput test], a two-stage coronavirus disease 2019 testing strategy, using a barcoded isothermal NASBA 
reaction. It combines point-of-care diagnosis with next-generation sequencing, aiming to achieve population- 
scale testing. Stage 1 allows a quick decentralized readout for early isolation of presymptomatic or asymp-
tomatic patients. It gives results within 1 to 2 hours, using either fluorescence detection or a lateral flow 
readout, while simultaneously incorporating sample-specific barcodes. The same reaction products from 
potentially hundreds of thousands of samples can then be pooled and used in a highly multiplexed sequencing–
based assay in stage 2. This second stage confirms the near-patient testing results and facilitates centralized 
data collection. The 95% limit of detection is <50 copies of viral RNA per reaction. INSIGHT is suitable for 
further development into a rapid home-based, point-of-care assay and is potentially scalable to the population 
level.
INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic is caused by 
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
virus (1). Pandemic control has been challenging because of the long 
incubation period and high percentage of asymptomatic carriers of 
this disease (2, 3). Nucleic acid testing is thus essential to identify and 
isolate infected individuals at an early stage to stop the spread of the 
virus. At the moment, the mainstream nucleic acid test relies on a 
reverse transcription polymerase chain reaction (RT-PCR) assay, per-
formed on nasopharyngeal and/or oropharyngeal swabs (4). It re-
quires labor-intensive RNA extraction and expensive equipment such 
as a thermocycler. The complexity, cost, and availability of RNA 
extraction kits and thermocyclers have limited the throughput of 
these RT-PCR assays. Hence, although the current testing regime, 
in conjunction with the lockdown measures, has successfully brought 
down the reproduction number R of the disease to below 1 in many 
countries, ramping up testing capacity sufficiently to maintain R be-
low 1 will be challenging once social activities return to normal. At 
the same time, a prolonged lockdown is highly detrimental to the 
economy and the physical and mental health of individuals. Regular, 
high-throughput testing with rapid results is one way out of the current 
conundrum. Several point-of-care diagnostic tests have been proposed, 
and some already authorized for use around the world, including 
SAMBA II (5), Abbott ID NOW (6), and many others. However, 
they typically require relatively expensive instruments or reagents, 
thus limiting their widespread adoption at a population level.
The ideal test would have the following five features: It would be 
accurate, cheap, scalable, portable, and fast. This would allow for 
decentralized and frequent testing of a large proportion of the pop-
ulation, even in countries with limited medical resources. Numerous 
groups are working on near-patient tests (7–13) aimed at improving 
testing capacity and ultimately achieving regular populational scale 
testing. However, it is difficult to control for patient operational error, 
and it is also challenging for centralized data collection. Centralized 
testing using a next-generation sequencing (NGS) readout (14) has 
also been proposed, which allows efficient scaling of testing and 
simple data collection, but patients do not have immediate access to 
the testing results, thus delaying the early isolation of presymptomatic 
or asymptomatic patients. Here, we propose INSIGHT [isothermal 
NASBA (nucleic acid sequence–based amplification) sequencing–
based high-throughput test], a two-stage testing strategy, using a 
combination of isothermal NASBA and NGS technologies, combin-
ing the advantages of near-patient and centralized testing (Fig. 1A). 
The first stage of INSIGHT is the NASBA reaction, which can gen-
erate rapid test results on the spot in 1 to 2 hours. The second stage 
uses NGS to improve the test accuracy in a highly scalable way. Below, 
we describe the two stages of INSIGHT in detail.
The first stage consists of an isothermal NASBA reaction (Fig. 1B) 
with crude saliva as sample input that could be incorporated into a 
point-of-care or home-based kit. NASBA uses reverse transcription 
and T7 RNA polymerase–mediated in vitro transcription to rapidly 
amplify RNA of interest. More than a billion-fold amplification can 
be typically achieved in less than 2 hours (15). Compared to RT-PCR, 
the isothermal nature of NASBA means that special equipment, such 
as thermocyclers, are not needed. NASBA reactions amplify both 
RNA and DNA, providing unique advantages for the dual-stage 
diagnosis. For the rapid testing stage, the single-stranded RNA can 
bind efficiently to complementary oligonucleotides without prior 
denaturation. A fluorescent molecular beacon can thus be used as a 
readout to monitor the amplification in real time and yield rapid test 
results (16). Furthermore, we also established a lateral flow assay for 
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Fig. 1. INSIGHT: an all-in-one platform for two-stage COVID-19 detection. (A) Schematic outline of our proposed two-stage testing strategy. Stage 1 is a rapid, portable 
decentralized COVID-19 test. Saliva can be collected directly into a tube containing QuickExtract lysis buffer at home or point of care. After heating up to 95°C to lyse the 
virus and inactivate proteinase K, the lysate can be transferred into the NASBA reaction and incubated at 41°C. After 1 to 2 hours, the result can be directly visualized with 
a portable fluorescence detector or lateral flow assay. In stage 2, individuals can post the used reaction mixture to a local sequencing center. All samples are pooled and 
sequenced after a one-step universal PCR. (B) Barcoded NASBA with dual readout for COVID-19 detection. In the NASBA reaction, a sample-specific left barcode is inserted 
between the sequencing adaptor and the forward primer, and a right barcode is inserted between the T7 promoter and the reverse primer. The NASBA in vitro transcribed 
RNA product can be used to carry out either a portable fluorescence detection assay or a dipstick-based lateral flow assay for rapid results. Afterward, the NASBA products 
can be pooled and sequenced. RNase H, ribonuclease H; IVT, in vitro transcription.
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a quick and cheap dipstick-based readout. The second stage uses NGS 
to further improve the test accuracy and reduce user errors in a highly 
scalable manner. To achieve multiplexed sequencing, a sample- 
specific barcode pair can be incorporated into the amplified sequence 
(amplicon) during the first-stage reaction. The stage one end product 
can then be sent to a central facility for pooled sequencing, allowing 
up to hundreds of thousands of samples to be analyzed on a single 
next-generation sequencer. Here, the DNA in the NASBA end prod-
uct is more stable and less susceptible than the RNA to degradation 
during the sample shipment process. NGS may also substantially 
reduce any possible false-negative or false-positive results.
Furthermore, the INSIGHT technology can be viewed as a mod-
ular system, with the first stage consisting of two rapid test modules 
(either fluorescence or dipstick based) and the second stage a se-
quencing module. These modules can be used alone or combined in 
different ways, making INSIGHT highly flexible to adapt to different 
testing needs and resource availability. For example, for areas without 
adequate sequencing facilities, the rapid test modules (fluorescence 
or lateral flow based) in stage 1 could be used as standalone tests. In 
other cases, where accessing NGS is not a limiting factor and quick 
assay turnaround time could be achieved by well-established logis-
tics and NGS infrastructure, the NASBA reaction with sequencing 
(stage 2) could be applied alone, reducing the need for fluorescence 
detectors or purchasing the lateral flow/dipstick consumables. In an 
ideal situation, both stage 1 and stage 2 could be combined, providing 
the benefits of both rapid and scalable diagnosis as well as central-
ized validation and data collection.
RESULTS
INSIGHT technology development and optimization
Primers were designed to target the SARS-CoV-2 S gene, which en-
codes the viral envelope spike glycoprotein. The S gene is one of the 
most highly expressed viral RNAs (17) and, at the same time, is a 
promising target for SARS-CoV-2 vaccine development (18). In addition, 
the S gene sequence is an informative sentinel for viral genome evolution 
with respect to increased or decreased affinity to human viral entry 
receptors such as angiotensin-converting enzyme 2 (ACE2) (19). We 
screened 13 pairs of primers and selected the most efficient pair to opti-
mize our in-house NASBA reaction (fig. S1A). All subsequent reactions 
and figures shown in this paper were carried out with primer pair P8 
(see Materials and Methods). We have performed a homology search 
using nucleotide BLAST (20) and did not find significant homology 
between the P8 primers and any sequence present in a list of com-
mon respiratory microorganisms (list attached in table S2). With 
synthetic SARS-CoV-2 RNA as the input, we have achieved target 
RNA amplification with both our in-house NASBA mixture and a 
commercial ready-made mixture. The NASBA reaction product was 
confirmed by an RNA urea gel (fig. S1B), showing a product of the 
expected size in the presence of viral template RNA only. Further-
more, we also optimized the primer concentration used in the NASBA 
reaction by quantifying the NASBA end product RNA concentra-
tion with a molecular beacon (fig. S1C). We found that a primer 
concentration of 25 nM each, which is 10 times less than typically 
used in the literature (21–23), increased the reaction efficiency. Ad-
ditional optimization has been carried out for our in-house NASBA 
reaction mixture. This includes the choice of enzymes (ProtoScript II 
reverse transcriptase instead of avian myeloblastosis virus reverse 
transcriptase; fig. S1D), the concentration of enzymes (higher con-
centration with better yield and more consistent results; fig. S1E), 
and the buffer pH (fig. S1F).
To work toward an INSIGHT test that can be used at home and to 
simplify the assay workflow and improve its scalability, the NASBA 
reaction would ideally be applied to a crude saliva lysate. This would 
alleviate the need for complex and expensive processes to purify RNA. 
Commercially acquired human saliva can be mixed with QuickExtract 
buffer and heat-treated at 95°C for 5 min to generate saliva lysate 
(24). Here, we demonstrate that saliva lysate is compatible with the 
NASBA reaction using commercially available human saliva from 
healthy individuals with spiked-in synthetic viral RNA. To minimize 
the handling steps, saliva lysate is combined with partial NASBA 
mix (without the enzyme cocktail) and heated at 95°C for 5 min 
to inactivate proteinase K and disrupt RNA secondary structure 
(fig. S2A). This suggests that in practice, the 95°C denaturation step 
could be combined with the 95°C viral lysis step to save an extra 
heating step. The method performs well, with 100 copies of input 
RNA reliably detected.
Last, to achieve better assay sensitivity, we also varied saliva lysate 
input volume to find the maximum compatible saliva input amount. 
We found that saliva lysate can be increased from 1 to 3 l in a total 
reaction volume of 20 l and the detection threshold was not com-
promised (fig. S2B).
INSIGHT stage 1 (option A): Fluorescence readout 
with molecular beacon detection
We have established two forms of specific readouts for stage 1 of 
INSIGHT: a molecular beacon with fluorescence detection and a 
dipstick-based lateral flow assay. We describe the performance of 
the former option here and the latter in the next subsection.
Molecular beacons are hairpin-shaped molecules with a fluoro-
phore and a quencher covalently attached and brought into close 
proximity due to the secondary structure formed by the hairpin. 
Upon recognition of the target, the fluorophore and the quencher 
will be spatially separated because of hybridization, which results in 
fluorescence (Fig. 2A). Here, four types of beacons were designed to 
target the P8 amplicon: a conventional DNA beacon, a toehold DNA 
beacon, a conventional 2′-O-methyl RNA beacon, and a toehold 
2′-O-methyl RNA beacon. The toehold provides an initial anchor 
point for the beacon to latch onto its target and assists in the un-
winding of the stem of the beacon, and the 2′-O-methyl modification 
increases target affinity and provides stability against oligonucleotide 
degradation. All four types were first tested with in vitro transcribed 
RNA, and the 2′-O-methyl RNA toehold beacon was found to achieve 
the best sensitivity (Fig. 2B). Therefore, we chose the RNA toehold 
beacon for our COVID-19 NASBA assay. An essential feature of this 
beacon is a 3′-propyl group that prevents any possibility of poly-
merase extension of the toehold sequence.
We have also titrated the concentration of the toehold RNA beacon 
in the reaction mixture to achieve the best real-time results, as a high 
beacon concentration inhibits the NASBA reaction (fig. S1G). We 
found that 20 nM molecular beacon resulted in the best assay sensi-
tivity. With this beacon concentration, the fluorescence reaches a 
plateau at around 40 to 60 min into the reaction. With the non-
barcoded primer pair P8, the real-time detection limit is around 100 to 
1000 copies per reaction for our in-house mixture and around 
10 copies per reaction for the commercial mixture (Fig. 2C).
To incorporate patient-specific barcodes in the NASBA reaction, 
we have designed the primers with 5–nucleotide (nt) barcodes flanked 
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Fig. 2. INSIGHT stage 1 fluorescence readout with molecular beacon detection. (A) Illustration of conventional and toehold molecular beacons. (B) Sensitivity of 
different types of molecular beacons. Four different types of beacons were mixed with increasing amounts (0.2 to 2000 ng) of in vitro transcribed target amplicon RNA for 
a fluorescence readout. (C) In-house and commercial NASBA mixtures with varying amounts (101 to 106 copies) of input viral RNA templates and a real-time molecular 
beacon readout. With a final concentration of 20 nM beacon in the reaction, fluorescence was detectable at around 30 min and reached saturation at around 60 min. 
(D) Schematic illustration of the barcoded NASBA DNA product. Using the primer pair P8, the forward (FWD) primer contains a 24-nt sequence targeting part of the SARS-
CoV-2 S gene, a 5-nt left barcode, and a 33-nt sequence of the Illumina sequencing adaptor. The reverse (REV) primer contains a 22-nt sequence complementary to part 
to SARS-CoV-2 S gene, a 5-nt right barcode, and a 31-nt T7 promoter. Customized sequencing primers can be used for the reverse read. (E) With barcoded primers, the 
NASBA reaction achieved a detection threshold of around 10 to 100 copies of viral RNA per 20 l of reaction for the commercial NASBA mixture (two replicates). (F) Left: 
Schematic illustration of experimental setup with 5 min at 95°C to denature the viral RNA, followed by 1.5 hours at 41°C for the NASBA reaction. Right: Real-time INSIGHT 
stage 1 fluorescence readings for samples with 0, 10, 50, and 100 copies of viral RNA per 20 l of reaction (six technical replicates each).
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on each side and an Illumina handle on the forward primer (sequences 
shown in Table 2) so that the NASBA DNA product would contain 
a 5-nt barcode at each end (Fig. 2D). The NASBA reaction still 
worked with the barcoded primers, despite a slightly reduced detec-
tion threshold of around 10 to 100 copies per reaction for the com-
mercial NASBA mixture (Fig. 2E). By using combinatorial barcoding, 
a 5-nt barcode sequence on both sides can generate up to a million 
unique barcodes or 16,384 Hamming distance three-separated bar-
codes. The latter allows single-nucleotide substitution error in the 
barcodes to be corrected after sequencing. If needed, then a 6-nt 
barcode on each primer can generate 262,144 Hamming distance 
three-separated unique barcode pairs (note S1).
We assessed the performance of INSIGHT stage 1 with real-time 
fluorescence detection using human saliva from healthy individuals 
with spiked-in synthetic viral RNA, following temperature setting 
(2) in step 2 option A in Materials and Methods (Fig. 2F). For sam-
ples with input of 50 viral RNA copies per 20 l of reaction, all six 
reactions showed amplification of fluorescence signals, whereas for 
samples with input of 10 viral RNA copies per 20 l of reaction, two 
of six reactions showed amplification.
INSIGHT stage 1 (option B): Dipstick readout with  
lateral flow assay
We have also developed and optimized a dipstick-based lateral flow as-
say as an alternative to fluorescence detection in stage 1 of INSIGHT. 
Compared to molecular beacon detection where a portable fluores-
cence detector is needed, dipstick-based detection is a particularly 
attractive option, as it does not require any extra equipment apart 
from a portable heating source.
Here, we use a format of lateral flow assay that detects nucleic acid 
using neutravidin-conjugated carbon nanoparticles (NA-CNPs) that 
can bind to biotin, a test line comprising an anti-FAM (fluorescein 
amidite) antibody and a biotin control line (C-line) to capture 
excess NA-CNPs. Two RNA capture oligos are added into the 
NASBA reaction. One is FAM labeled, and the other is biotin la-
beled. During the reaction, both capture oligos bind to different 
parts of the single-stranded RNA NASBA product. The dual tag-
ging of FAM and biotin results in aggregation of NA-CNPs at the 
test line, resulting in a visible signal in the assay (Fig. 3A). A positive 
lateral flow assay would show a clearly visible line at test line 2  in 
addition to the C-line, whereas only the C-line is visible in a nega-
tive assay. By using the commercially available lyophilized NASBA 
mix, samples at the end of the NASBA reaction can be directly 
loaded onto the dipstick without any extra step of RNA purification 
or dilution (see step 2 option B in Materials and Methods for details).
We also assessed the performance of INSIGHT stage 1 with 
dipstick detection using human saliva from healthy individuals with 
spiked-in synthetic viral RNA (Fig. 3C). Three technical repeats were 
performed for different amounts of viral RNA input. This success-
fully detected viral RNA with input of 50 copies per 20 l of reaction 
and failed to detect samples with input of 10 copies per 20 l of re-
action. We used barcoded primers in the reactions here to make the 
stage 1 product compatible with stage 2 sequencing.
We note that it is necessary to use the lyophilized mix to achieve 
a sample-to-dipstick result without any extra steps. We have also 
tried using the commercially available liquid NASBA mix but found 
that it required an extra step of dilution before the lateral flow as-
say (Fig. 3B), possibly due to a component within the liquid mix 
Fig. 3. INSIGHT stage 1 dipstick readout with lateral flow assay. (A) Schematic illustration of the nucleic acid lateral flow assay. (B) Lateral flow–based dipstick test results 
from NASBA reactions using liquid NASBA mix. The lateral flow assay works when the NASBA end product is diluted 50 times with PCRD buffer but not with undiluted NASBA end 
product. (C) Left: Schematic illustration of experimental setup with 5 min at 95°C to denature the viral RNA, followed by 1.5 hours at 41°C for the NASBA reaction. Lyophilized 
NASBA mix is used in the reaction. The NASBA end product can be directly loaded onto the dipstick. Results can be read after 10 min of incubation at room temperature. 
Right: All three technical replicates for 50 copies viral RNA per 20 l of reaction were detectable using the dipstick assay. Photo credit: Qianxin Wu, Wellcome Sanger Institute.
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interfering with the downstream lateral flow assay. In addition, 
we previously attempted to use biotinylated uridine 5′-triphosphate 
(UTP) and FAM-tagged RNA capture oligo for dual tagging. How-
ever, this combination requires an extra step of RNA purification 
after the NASBA reaction to prevent unused biotinylated UTP from 
saturating the NA-CNPs (fig. S3). In summary, we have optimized 
the conditions such that the lyophilized mix allows direct sample- 
to-result readout.
INSIGHT stage 2: Pooled library construction and  
NGS readout
After the NASBA reaction, which can occur in a near-patient setting, 
we propose that the INSIGHT stage 1 products can be transported 
to a local sequencing center. As sample-specific barcodes would have 
already been incorporated in stage 1 in a decentralized manner, all 
samples can be directly pooled, and the NGS library can be prepared 
with a simple one-step PCR using primers flanked with sequencing 
adapters (Fig. 4A and see step 3 in Materials and Methods for details).
We designed an experiment with 48 contrived samples (Fig. 4B). 
Each reaction used a unique pair of barcoded primers. We varied 
the input of the viral RNA as shown in Fig. 4B to mimic the wide 
range of viral load in patient samples. The first stage of INSIGHT 
was carried out with real-time fluorescence detection. For samples 
with input of 50 viral RNA copies per 20 l of reaction, five of six 
reactions showed amplification of fluorescence signals, whereas for 
samples with input of 10 viral RNA copies per 20 l of reaction, two 
of six reactions showed amplification (Fig. 4B). For the second-stage 
sequencing, we performed two pooling strategies either independent 
of the first-stage results or dependent on the first-stage results. 
“All pool” included all 48 samples regardless of the first-stage results. 
“Negative pool” was the collection of the 17 samples that showed 
negative results in the first stage. Library preparation was performed 
separately for all pool and negative pool.
Figure 4C shows the read counts from all samples in all pool. In 
addition to reads that contain the expected barcode pairs, we also 
observed some reads with left and right barcode combinations that 
were not used in the experiment, a phenomenon we refer to as 
“barcode hopping.” Among the 17.4 million reads (excluding PhiX 
reads) generated by MiSeq, 4.96 million reads match the expected 
amplicon (see step 4 of the “Experimental protocol” section) up to 
two substitution errors, of which 4.53 million reads contained used 
barcode pairs and 0.43 million reads were generated from barcode 
hopping. The two dotted lines in the plot of Fig. 4C indicate the 
median and the maximum read counts of all hopped barcode pairs. 
Read counts from samples with 50 viral RNA copies and 10 viral 
RNA copies showed that five of six and two of six, respectively, had 
higher read counts than the maximum read count of hopped bar-
code pairs, providing an identical result to the fluorescent readout. 
In this particular experiment, both left and right barcodes in every 
sample are unique, i.e., no two samples share the same left or right 
barcode. Therefore, hopped barcode pairs can be unambiguously 
identified and evaluated in this experiment.
To increase the available barcode pair combinations for multi-
plexing, repeated usage of the same left or right barcode is desirable. 
We have thus sought to evaluate and potentially circumvent the 
barcode hopping problem and have built a statistical model (note S2) 
to predict the number of reads generated from barcode hopping. If 
the observed read count of a barcode pair is significantly larger than 
the predicted read count (z score exceeding 100), then the barcode 
pair is likely to be a real product of NASBA amplification, i.e., a posi-
tive result. Using the above calling procedure, we can unambiguously 
identify 31 of the 36 samples with viral RNA input as “positive” and 
all 12 negative control samples as “negative” in all pool (Fig. 4D). 
This result is identical to the stage 1 fluorescence result.
We also performed a correlation analysis between the INSIGHT 
stage 1 speed of signal amplification (measured as the reciprocal of 
time to reach a normalized fluorescence level of 0.2) and the stage 2 
read counts. As expected, there is a strong positive correlation be-
tween the results from the two stages (Pearson R = 0.67, P < 0.0001; 
see Fig. 4E). Although the input RNA varied from 10 to 106 copies 
per reaction, the INSIGHT stage 2 read counts for amplified sam-
ples only differed by 14-fold. This showed that the NASBA reaction 
in stage 1 had saturated for most samples, thus allowing stage 2 to 
handle samples across an extremely wide dynamic range of viral 
RNA input molecules.
Figure 4F shows the read counts from all samples when sequenced 
in the negative pool. One sample, which had 50 copies of viral RNA 
as input and failed to be picked up as positive in stage 1, showed 
positive read counts in stage 2. This means that stage 2 sequencing 
can further improve the sensitivity of stage 1 results. INSIGHT 
stage 1 and stage 2 combined results are summarized and shown in 
Fig. 4G.
INSIGHT performance evaluation and comparison with  
RT quantitative PCR
We next sought to summarize the limit of detection (LoD) for the 
INSIGHT technology. Here, LoD-95 was defined to be the input 
viral RNA amount at which 95% of samples can be detected. This is 
estimated by maximum likelihood estimation under the assumption 
that the number of viral RNA copies in the reaction input follows a 
Poisson distribution and that each molecule has the same probability 
of being amplified. INSIGHT stage 1 with a fluorescence readout 
attains an estimated LoD-95 of 46.6 [95% confidence interval (CI), 
37.8 to 56.8] copies per 20 l of reaction (Fig. 5C). This is calculated 
on the basis of the 24 reactions shown in Fig. 2F, the 48 reactions 
shown in Fig. 4B, and additional 327 reactions shown in Fig. 5A and 
fig. S4. Please note that all barcodes used are randomly selected. The 
high number of successful amplifications at low copy viral input 
(50 copies per reaction in Fig. 5A and 100 copies per reaction in fig. S4) 
indicates that the proportion of the barcodes that might interfere 
with the NASBA reaction is very low. Separately, INSIGHT stage 1 
with dipstick readout has an LoD-95 of 75.8 (95% CI, 24.9 to 234) copies 
per 20 l of reaction, which is computed using reactions shown in 
Fig. 3C. For the second stage, using the all pool results shown in 
Fig. 4C, we calculated that the NGS sequencing alone has an LoD-95 
of 80.3 copies (95% CI, 37.7 to 197) per 20 l of reaction. By combining 
the stage 1 fluorescence readout and stage 2 negative pool results, 
the overall INSIGHT technology LoD-95 can be further improved 
to 37.8 (95% CI, 16.2 to 57.1).
To put our LoD figures in context, we compared our method with 
the gold-standard reverse transcription quantitative PCR (RT-qPCR) 
assay. We performed RT-qPCR (Fig. 5B) following the protocol rec-
ommended by the Public Health England (PHE) (25). Chemically 
synthesized viral RNA was used as sample input. Four technical 
replicates each were carried out with and without saliva lysate from 
healthy individuals. The RT-qPCR could consistently detect samples 
with 50 copies of viral RNA per 20 l of reaction. With 10 copies of 
viral RNA per 20 l of reaction, it detected three of four samples 
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Fig. 4. INSIGHT stage 2 pooled testing using NGS. (A) Strategy for stage 2 NGS-based detection. Up to hundreds of thousands of samples can be potentially pooled 
together, and a universal indexing PCR can be carried out at a local sequencing center. (B) Real-time molecular beacon readings for 48 barcoded primer pairs with various 
amounts (0 to 106 copies) of viral RNA input per 20 l of reaction. (C) INSIGHT stage 2 read counts for samples from all reactions in (B) i.e., all pool. The two dotted lines 
show the median and the maximum of barcode hopping read counts. (D) The z score distribution of used barcode pairs and hopped barcode pairs using statistical mod-
eling. Red dots, used barcode pairs; black dots, hopped barcode pairs. (E) Correlation analysis of INSIGHT stage 1 speed of amplification (reciprocal of time to reach 
0.2 normalized fluorescence reading) and stage 2 sequencing read counts. (F) INSIGHT stage 2 read counts for samples from 17 reactions in (B) that showed negative re-
sults in stage 1 fluorescence detection, i.e., negative pool. All but one samples had 0 count. (G) Combined results from both stage 1 and stage 2. The color of the heatmap 
represents INSIGHT stage 1 speed of amplification with the same sample order in (B). Samples that were positive in INSIGHT stage 2 all pool sequencing results are boxed 
in red. Samples that were positive in INSIGHT stage 2 negative pool sequencing results are boxed in green. Samples that were negative in both all pool and negative pool 
sequencing results are boxed in black.
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Fig. 5. INSIGHT technology LoD and comparison with RT-qPCR. (A) Real-time molecular beacon readings for 164 randomly selected barcoded primer pairs with 
50 copies of viral RNA input per 20 l of reaction. Empty wells are boxed in green, and samples that failed to be amplified are boxed in red. (B) The qPCR cycle number to 
reach fluorescence threshold using the Public Health England (PHE) protocol and various numbers of viral RNA copies per 20 l of reaction as input. (C) The estimated 95% 
LoD (LoD-95) for different stages of INSIGHT and gold-standard RT-qPCR, with the whiskers spanning the 95% CIs of the estimates.
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with saliva lysate and only one of four without saliva lysate. Thus, 
the estimated LoD-95 for the RT-qPCR is 55.3 (95% CI, 20.2 to 149) 
copies per 20 l of reaction without saliva and 21.4 (95% CI, 7.3 to 70.5) 
copies per reaction with 1 l of saliva lysate added in the reaction. In 
summary, the INSIGHT protocol is highly comparable to the PHE 
RT-qPCR protocol in terms of sensitivity.
DISCUSSION
INSIGHT’s dual-stage design combines the benefits of both near- 
patient testing and centralized testing. It offers a rapid first-stage 
readout without delay and minimizes the problem of RNA degrada-
tion. The distributed first stage also reduces the logistic burden and 
labor requirements for carrying out population-scale screening. The 
centralized second stage can be used to eliminate user errors, collate 
results in a centralized repository, and help inform other epidemio-
logical efforts. In particular, when screening asymptomatic individuals, 
it is crucial to control false positives, which often requires a confir-
matory test for all positive samples. Our second stage here can nat-
urally act as a confirmatory test of near-patient first-stage results. In 
addition, INSIGHT’s two stages can be viewed as three different 
modules, two rapid detection modules (fluorescence detection or 
dipstick-based detection) and one sequencing module. The modules 
can be either combined in a two-stage test as illustrated here or used 
independently. This offers flexibility for adaptation to local needs 
and resources and for testing other viruses.
Our assay sensitivity is comparable to the gold-standard RT-qPCR 
test. Although INSIGHT has shown promising results in experimental 
settings, additional work is required to bring it into practical use. 
The current experiments were carried out using saliva from healthy 
individuals with spiked-in viral RNA rather than patient samples. 
However, our estimated LOD-95 of 37.8 copies per reaction (which 
can have 0.5 to 1.5 l of saliva input) is well below the median viral 
load of 7796 copies/l (interquartile range of 408 to 215,500 copies/l) 
in patients’ saliva for the first 7 days from symptom onset (26).
In addition, several techniques we developed as part of the 
INSIGHT technology may be of interest in other contexts. First, we 
show that toehold beacons can achieve a much higher sensitivity 
than commonly used regular molecular beacons for fluorescence 
detection. Second, the use of two RNA capture oligos with different 
tags in the INSIGHT stage 1 dipstick readout offers a way to detect 
RNA in a lateral flow assay and further increases specificity for a 
particular target sequence. Last, we have established a statistical 
model to address the problem of barcode hopping that can be used 
in any multiplexed NGS settings.
Other isothermal methods have been proposed for SARS-CoV-2 
detection. Most of them are based on the reverse transcription loop- 
mediated isothermal amplification (RT-LAMP) technology with a 
colorimetric or turbidimetric readout (7–10). These assays could 
potentially suffer from false-positive results generated from non-
specific primer binding or primer dimers (11). To circumvent this, 
Joung et al. (12) and Broughton et al. (13) have proposed to use a 
CRISPR-based assay to achieve highly specific test results. A major 
advantage of INSIGHT is to enable a rapid readout with high spec-
ificity for SARS-CoV-2, while avoiding complex additional steps 
such as CRISPR-based cleavage. In the first stage, a molecular 
beacon for fluorescence readout or RNA capture oligos for lateral 
flow readout provides an additional layer of sequence-specific 
detection. In the second stage, NGS further improves the assay 
sensitivity and specificity by unambiguously identifying the viral 
sequence. We have not observed any false-positive results in all our 
stage 1 and stage 2 experiments. We note that, unlike the concatemer 
amplification product in LAMP, the NASBA reaction generates a 
single, well-defined amplicon, thus making it particularly suitable 
for sequencing. Furthermore, it allows combinatorial barcoding, 
thus avoiding the need to synthesize hundreds of thousands of bar-
coded oligonucleotides.
Table 1. Reagents. DTT, dithiothreitol; DMSO, dimethyl sulfoxide; dNTP, 
deoxynucleotide triphosphate; NTP, nucleotide triphosphate; BSA, bovine 
serum albumin; HS, high sensitivity; dsDNA, double-stranded DNA; qPCR, 


















Tris (1 M) (pH 8), RNase 
free Invitrogen AM9855G
Sodium hydroxide Sigma-Aldrich 71687
1 M MgCl2 Invitrogen AM9530G
2 M KCl Invitrogen AM9640G
DTT Sigma-Aldrich 43816
DMSO Sigma-Aldrich 276855
dNTP set (100 mM) Invitrogen 10297018
NTP set (100 mM) Thermo Fisher Scientific R0481
RNase H NEB M0297L
ProtoScript II reverse 
transcriptase NEB M0368S
T7 RNA polymerase NEB M0251L
BSA (20 mg/ml) NEB B9000S
PCRD lateral flow 
immunoassay Abingdon Health FG-FD51673
Qubit RNA HS Assay Kit Invitrogen Q32852
Qubit dsDNA HS  
Assay Kit Invitrogen Q32851
PowerUp SYBR Green 
qPCR Master Mix Applied Biosystems 15340939
Normal human saliva MyBioSource MBS170210
QIAquick PCR 
Purification Kit QIAGEN 28104
KAPA HiFi HotStart 
ReadyMix PCR Kit Kapa Biosystems KK2600
AMPure XP Beckman Coulter A63882
MiSeq Reagent Kits v2 
(300 cycles) Illumina MS-102-2002
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Table 2. Oligonucleotide sequences.  
NASBA primers (P8)
Forward primer CCAGCAACTGTTTGTGGACCTA
Reverse primer with T7 
handle aattctaatacgactcactatagggagaaggACACCTGTGCCTGTTAAACCAT
Forward primer with 5-nt 
barcode and Illumina 
handle
tgactggagttcagacgtgtgctcttccgatctnnnnnCCAGCAACTGTTTGTGGACCTA
Reverse primer with 5-nt 
barcode and T7 handle aattctaatacgactcactatagggagaaggnnnnnACACCTGTGCCTGTTAAACCAT
Toehold molecular beacon (2′-O-methyl RNA)
FAM-AUUGACAGUCUACUAAUUUGGUUAAAAACAAAUGUGUCAA-BHQ1dT-UUCAACUUCAAUG-propyl
P8 RNA capture oligos for PCRD
Probe A FAM-AAAAGUCUACUAAUUUGGUUAAAA
Probe B ACAAAUGUGUCAAUUUCAACUUCA-Biotin
Library construction PCR primers
P5 end primer AATGATACGGCGACCACCGAGATCTACACNNNNNNNNAGCCAGCTCTGGAGAATTCTAATACGACTCACTATAGGGAGAAGG
P7 end primer CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT
Customized NGS primer (T7 
containing) AGCCAGCTCTGGAGAATTCTAATACGACTCACTATAGGGAGAAGG
Table 3. INSIGHT reaction mixtures.  
Life Sciences reaction mixture (RM)
Volume Stock concenctration Concentration in RM
Saliva lysate 1 l
Primers/beacon mix 1 l
500 nM each primer 25 nM each primer
400 nM beacon 20 nM beacon
Spiked-in viral RNA/water 3 l
Buffer (NECB-24) 6.7 l
Nucleotide (NECN-24) 3.3 l
Enzyme mix (NEC-1-24) 5 l
Total volume 20 l
In-house reaction mixture
Volume Stock concentration Concentration in RM
Saliva lysate 1 l
Primers/beacon mix 1 l
500 nM each primer 25 nM each primer
400 nM beacon 20 nM beacon
Spiked-in viral RNA/water 4 l
Buffer with DMSO* 5 l
Nucleotide mix* 4 l
Enzyme mix* 5 l
Total volume 20 l
 *See table S1 for detailed composition.
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While different research groups [e.g., (14)] and companies [e.g., 
COVIDSeq (27) from Illumina and SwabSeq (28) from Octant] have 
proposed to use NGS to expand testing capacity, most of them are 
RT-PCR based, restricting amplification and barcoding to central-
ized facilities. The decentralized first-stage NASBA reaction in 
INSIGHT greatly reduces the burden of sample handling in testing 
centers and, hence, makes regular population-scale screening feasible. 
Other groups including (11, 29–31) have also independently suggested 
similar approaches of barcoded isothermal amplification. We have 
summarized the main features of a few representative COVID-19 
testing technologies, including INSIGHT, in table S3.
Our system can also be modified to include additional primers 
targeting a different region of the SARS-CoV-2 genome or other 
pathogens, making it possible to multiplex detection or apply the 
technology to novel pathogen outbreaks. In addition, an internal 
positive control RNA sequence that can be amplified by one of the 
same primer pairs, or a separate primer pair targeting human RNA, 
can be added to the reaction to ensure that a negative result is not 
due to faulty reagents or patient handling mistakes and to provide 
some degree of quantification of viral load. The global COVID-19 
emergency has exposed our weaknesses in responding to a new 
pathogen and an emerging pandemic, and we hope that the INSIGHT 




Reagents and oligonucleotides used are listed in Tables 1 and 2. The 
molecular beacons were synthesized using a K&A H-8 SE DNA 
synthesizer and purified by reverse-phase high-performance liquid 
chromatography (ATDBio). Molecular beacons are reconstituted 
with annealing buffer [10 mM tris (pH 8) with 10 M MgCl2] to the 
final concentration of 10 M and then annealed by incubation at 
85°C for 5 min and then gradual cooling to 4°C by 0.1°C/s before 
the NASBA reaction.
Step 1: Lysis of saliva samples
Mix crude saliva (commercial pooled human saliva from healthy 
individuals) at 1:1 ratio with QuickExtract DNA Extraction Solution. 
Incubate at 95°C for 5 min to ensure complete lysis of virus and in-
activation of proteinase K.
Step 2 (option A): NASBA reaction with fluorescence detection
Take 1 l from the product of step 1 (saliva lysate) and add into the 
NASBA reaction mixture (without the enzyme mix) to make a total 
volume of 15 l. Reaction mixture can either be prepared in-house 
or from the Life Sciences NASBA liquid kit (see Table 3 below) us-
ing one of the two temperature settings below.
1) Reaction mixture without the enzyme mix is incubated at 
65°C for 2 min, followed by a 10-min incubation at 41°C. Following 
that, 5 l of enzyme mix is added into the reaction and incubated at 
41°C for a further of 90 to 120 min.
2) Alternatively, reaction mixture without the enzyme mix is 
incubated at 95°C for 5 min, followed by a 10-min incubation at 
41°C. Following incubation, 5 l of enzyme mix is added into the 
reaction and incubated at 41°C for a further 90 to 120 min.
A fluorescence plate reader (e.g., FLUOstar) can be used to mon-
itor the reaction in real-time or as an end point assay.
Step 2 (option B): NASBA reaction with lateral flow  
dipstick detection
For detection with a lateral flow assay, a NASBA-lyophilized kit is 
used with the constitution of the reaction mixture shown in Table 4. 
Take 4 l from the product of step 1 (saliva lysate) and add into the 
NASBA reaction mixture (without the enzyme mix) to make a total 
volume of 60l. Incubate at 95°C for 5 min, followed by a 10-min 
incubation at 41°C.
Following that, 20 l of enzyme mix is added into the reaction 
and incubated at 41°C for a further of 90 to 120 min. Take the reac-
tion product to the sample well of a PCRD test cassette. Results will 
be shown within 10 min.
Step 3: Library construction for NGS
To allow for pooled sequencing of NASBA reaction end products, 
barcode sequences are added upstream of each of the forward and 




Saliva lysate 4 l
Primers 4 l
500 nM each 
primer




Probe A 1.92 l 1 M 24 nM











Total volume 80 l
Table 5. Library construction PCR conditions.  
Reaction mixture
Volume
2× PCR mix (KAPA HiFi HotStart ReadyMix) 20 l
P5 end primer (10 M) 1 l
P7 end primer (10 M) 1 l
Column-purified NASBA product  
(~3.5 ng dsDNA) 4 l
Nuclease-free water 14 l
Thermocycling conditions
Temperature Time Cycle number




72°C 4 min 1
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reverse primers (Fig. 4A). In addition, an Illumina sequencing adaptor 
is added upstream of the forward primer barcode sequence as a uni-
versal PCR handle (see Table 2 for the oligonucleotide sequences).
NASBA end products (2 l) from each sample are first pooled 
into a single tube. Pooled products are then column purified to 
remove residual NASBA primers (QIAquick PCR Purification Kit). 
PCR is performed on the column-purified pooled sample using two 
NGS indexing primers and the reaction mix and cycling parameters 
in Table 5. Here, we have designed a customized NGS primer con-
taining the T7 polymerase promoter sequence (see Table 2 for the 
oligonucleotide sequence) at the P5 end and used a standard TruSeq 
sequencing primer at the P7 side. A PCR mix is made on the basis of 
Table 5 below. A standard PCR program is used with longer elonga-
tion time and minimal cycle number to reduce barcode hopping.
After the PCR, an AMPure bead–based double size selection is car-
ried out (0.55× and 0.75×) to enrich for products of interest. In this 
study, NGS was carried out using 150–bp (base pair) paired-end MiSeq 
sequencing with MiSeq Reagent Kit v2 (300 cycles). Before sequencing, 
30% PhiX was added into the library to increase the complexity.
Step 4: Analysis of NGS results
To analyze the INSIGHT NGS data, sequences in FASTQ files are 
first trimmed to leave the first 80 nucleotides for both read 1 and 
read 2 using FASTX_trimmer. The trimmed read 1 and paired read 2 
are then merged by FLASH. The merged sequence is compared with 
the 102-nt reference viral genome sequence (NNNNNACACCTGT 
GCCTGTTAAACCATTGAAGTTGAAATTGACACATTT 
GTTTTTAACCAAATTAGTAGACTTTTTAGGTCCACAAA 
CAGTTGCTGGNNNNN, where N stands for the barcode posi-
tion), and only those with a Hamming distance of less than or equal 
to 2 are extracted. Here, only substitutions were allowed, while 
insertion- and deletion-containing reads were filtered out. The first 5-nt 
and the final 5-nt regions of all extracted sequences correspond, re-
spectively, to the right barcode and the reverse complement of the 
left barcode. Diagnostic results for sequenced NASBA samples are 
determined according to the read counts of their corresponding 
sample-specific barcode pairs (only sequences with exact barcode 
match were counted). More details can be found in Results.
Ethical statement
In accordance with guidance obtained from the Human Tissue 
Authority, there was no requirement to seek ethics committee ap-
proval for the use of commercially acquired human saliva, as test 
validation did not constitute research because it was determined 
to be “performance assessment” and sample donor consent was 
not required.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/7/eabe5054/DC1
View/request a protocol for this paper from Bio-protocol.
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